A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

3상 진행 중(모집 완료) NCT05388669

대상 질환	Advanced or Metastatic Non-small Cell Lung Cancer
임상 단계	3상
스폰서	Janssen Research & Development, LLC
상태	진행 중(모집 완료)
참여자 수	418 명
중재(약물)	Lazertinib, Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF), Amivantamab Intravenous
시작일	2022년 8월 5일
완료일	2024년 1월 3일
결과 공개일	2026년 2월 2일

요약

The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantamab, amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), for subcutaneous administration. This formulation has the potential to enhance both the patient and physician experience with amivantamab by providing easier and accelerated administration.

For All Regions Other Than the European Union (EU) and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State

Pre-dose on Cycle 4 Day 1 (each cycle of 28 days) · micrograms per milliliters (mcg/mL)

Arm A: Lazertinib With Amivantamab SC-CF	206 ± 39.1 micrograms per milliliters (mcg/mL)
Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion	144 ± 41.5 micrograms per milliliters (mcg/mL)

Cox regression model	1.427 (95% CI 1.266–1.610)

For EU and Any Applicable Region: Observed Serum Concentration (Ctrough) of Amivantamab

Pre-dose on Cycle 2 Day 1 (each cycle of 28 days) · mcg/mL

Arm A: Lazertinib With Amivantamab SC-CF	335 ± 32.7 mcg/mL
Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion	293 ± 31.7 mcg/mL

Cox regression model	1.145 (95% CI 1.040–1.261)

Area Under the Concentration (AUC) Time Curve of Amivantamab From Day 1 to Day 15 (AUC [Day 1-15]) of Cycle 2

Cycle 2: Arm A: pre-dose, 24, 48, 72, 96, 168, and 360 hours (hrs) post-dose on Day 1; Arm B: pre-infusion, end of infusion (EOI)+10 minutes, EOI+2, EOI+6, EOI+24, EOI+48, EOI+72, EOI+168, and EOI+360 hrs post dose on Day 1 · micrograms*hour per milliliters

Arm A: Lazertinib With Amivantamab SC-CF	135861 ± 30.7 micrograms*hour per milliliters
Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion	131704 ± 24.0 micrograms*hour per milliliters

Geometric mean ratio	1.032 (95% CI 0.976–1.090)

BENITIONS에서 보기 ClinicalTrials.gov 원문 보기

같은 질환의 다른 임상

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients W — AstraZeneca
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With — National Cancer Institute (NCI)
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Pos — National Cancer Institute (NCI)
Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage I — National Cancer Institute (NCI)
Premedication to Reduce Amivantamab Associated Infusion Related Reactions — Janssen Research & Development, LLC
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small — Daiichi Sankyo

전체 임상

이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.

English 한국어 日本語中文 Русский